Author

Manoj Kumar Pandey

Cooper Medical School of Rowan UniversityORCID 0000-0002-2767-2929Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Gavin P. RobertsoniD· 2 shared Krishne GowdaiD· 2 shared Robert J. Chitren· 2 shared Shantu AminiD· 2 shared Subash C. JonnalagaddaiD· 2 shared Tülin Budak-AlpdoǧaniD· 2 shared Jaikee Kumar SinghiD· 1 shared Omar S. Al‐OdatiD· 1 shared

Activity by Year

2022-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Gavin P. RobertsonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Novel Pan-ALDH Inhibitor KS100 Effectively Targets ALDH+/CD138- Stem-like Cells to Overcome Relapse in Multiple Myeloma

Robert J. Chitren, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Subash C. Jonnalagadda, Tülin Budak-Alpdoǧan, Manoj Kumar Pandey

This study identifies KS100, a pan-ALDH inhibitor, as effective in reducing ALDH expression and viability of multiple myeloma cells, particularly ALDH+/CD138- stem-like cells, potentially overcoming relapse.

bioRxiv · Mar 6, 2025 · PreprintMolecular Biology

Development of a Novel Bruton's Tyrosine Kinase Inhibitor that exerts Anti-Cancer Activities Potentiates Response of Chemotherapeutic Agents In Multiple Myeloma Stem Cell-Like Cells

Weam Othman Elbezanti, Omar S. Al‐Odat, Robert J. Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tülin Budak-Alpdoǧan, Manoj Kumar Pandey

This paper develops a novel BTK inhibitor, KS151, which effectively targets MM stem cell-like cells and enhances the response to chemotherapeutic agents.

Frontiers in Pharmacology · Sep 9, 2022Peer-reviewedMolecular Biology